Stifel Nicolaus Reiterates Their Buy Rating on Esperion (ESPR)

Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Esperion (ESPRResearch Report) today and set a price target of $112. The company’s shares opened today at $38.53, close to its 52-week low of $36.06.

Archila wrote:

“We are reiterating our Buy rating on ESPR shares after the company reported its 2Q19 financials and business update. We believe management continues to execute well, particularly on recently shoring up the company’s cash position and believe the signing of a ROW partnership (ex-EU) along with positive results from its Phase 2 study evaluating the BPA/ezetimibe combo in T2D patients could be catalysts for the stock in the near-term. While the read out of MDCO’s (NC, $34.51) Phase 3 studies for inclisiran (which are expected in 3Q19) are often brought up by investors as a headwind for shares, we would be buyers on any weakness as we continue to remain positive on BPA/combo’s commercial prospects as a LDL-C lowering agent given its efficacy and safety profile – particularly in statin intolerant patients and the fact it is an oral therapy which patients prefer.”

According to TipRanks.com, Archila is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -10.7% and a 28.1% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $88.29, which is a 129.1% upside from current levels. In a report released yesterday, Northland Securities also assigned a Buy rating to the stock with a $65 price target.

See today’s analyst top recommended stocks >>

Based on Esperion’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $87.38 million. In comparison, last year the company had a GAAP net loss of $45.73 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Esperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).